Repligen (RGEN)
(Delayed Data from NSDQ)
$138.82 USD
+4.33 (3.22%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $139.50 +0.68 (0.49%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$138.82 USD
+4.33 (3.22%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $139.50 +0.68 (0.49%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth B Momentum D VGM
Zacks News
Reata (RETA) Soars on Potential Omaveloxolone NDA Filing
by Zacks Equity Research
The FDA asks Reata (RETA) to submit a pre-NDA meeting request to discuss omaveloxolone study data and cancel its previous request for a more general Type C meeting, boosting chances of an early NDA filing.
Iovance (IOVA) Falls on Negative Lifileucel Regulatory Update
by Zacks Equity Research
Iovance (IOVA) announces delay in BLA submission for its lead pipeline candidate, lifileucel for metastatic melanoma due to potency assay issue.
3 Biotech Stocks to Keep an Eye On Amid the Coronavirus Mayhem
by Ekta Bagri
The focus on coronavirus treatments should maintain momentum for the volatile Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BNTX, RGEN and OVID to perform well.
Here's Why Ocugen (OCGN) Stock Has More Than Tripled This Year
by Zacks Equity Research
Ocugen's (OCGN) stock rides on the company's collaboration with India's Bharat Biotech to co-develop and commercialize the latter's COVID-19 vaccine, COVAXIN, for the U.S. market.
Bristol-Myers (BMY) Teams Up With Agenus for Antibody Program
by Zacks Equity Research
Bristol-Myers (BMY) obtains exclusive license for Agenus' antibody program, AGEN1777, for an upfront payment of $200 million and up to $1.36 billion in milestone payments.
Here's Why Entera Bio (ENTX) Stock Has Almost Tripled This Year
by Zacks Equity Research
Entera Bio's (ENTX) stock price is being driven by encouraging data from phase II study on EB613, its investigational orally delivered treatment for osteoporosis
Regeneron (REGN) Resumes Enrollment in Lymphoma Cohorts
by Zacks Equity Research
Regeneron (REGN) resumes enrollment in two patient cohorts of pipeline candidate, odronextamab, a CD20xCD3 bispecific antibody, after the FDA lifts partial clinical hold.
Incyte (INCY) Announces Positive Results From Vitiligo Study
by Zacks Equity Research
Incyte (INCY) announces positive data from phase III studies on ruxolitinib cream for the treatment of vitiligo.
Lilly's (LLY) Tyvyt BLA Accepted for Review by FDA for NSCLC
by Zacks Equity Research
Lilly (LLY) and Innovent's sintilimab, a PD-1 inhibitor, is marketed by the brand name of Tyvyt in China for two indications.
Bristol Myers (BMY) Announces New Data on Cardiovascular Candidate
by Zacks Equity Research
Bristol Myers (BMY) announces new positive data on mavacamten from a late-stage study at the American College of Cardiology's 70th Annual Scientific Session.
Repligen (RGEN) Enters Oversold Territory
by Zacks Equity Research
Repligen (RGEN) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Prothena (PRTA) Q1 Loss Wider Than Expected, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.
Bayer's (BAYRY) Q1 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Bayer (BAYRY) beat estimates for earnings and revenues for the first quarter of 2021.
Perrigo (PRGO) Q1 Earnings Miss Estimates, Revenues In Line
by Zacks Equity Research
Perrigo (PRGO) reports dismal first-quarter 2021 results. The COVID-19 pandemic continues to hurt the company's top line.
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.
Radius (RDUS) Q1 Loss Narrower than Expected, Revenues Lag
by Zacks Equity Research
Radius (RDUS) reports a narrower loss but misses on sales in the first quarter as lead drug sales decline.
Zacks.com featured highlights include: Herbalife, DaVita, Apple, Century Communities and Repligen Corp
by Zacks Equity Research
Zacks.com featured highlights include: Herbalife, DaVita, Apple, Century Communities and Repligen Corp
Endo's (ENDP) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter, driven by revived demand.
5 of the Best Stocks to Buy Now for Striking Earnings Growth
by Tirthankar Chakraborty
Herbalife (HLF), DaVita (DVA), Apple (AAPL), Century Communities (CCS) & Repligen (RGEN) are the top stocks that flaunt attractive earnings growth at present.
Puma (PBYI) Beats on Q1 Earnings, Ups Nerlynx Sales View
by Zacks Equity Research
Puma Biotech (PBYI) beats first-quarter estimates for both earnings and sales. Stock up.
Aerie's (AERI) Q1 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.
Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View
by Zacks Equity Research
Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021. Stock up.
Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 58.14% and 22.90%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Alexion (ALXN) Tops Q1 Earnings, Merger With AstraZeneca On Track
by Zacks Equity Research
Alexion (ALXN) tops earnings and sales in the first quarter of 2021. Its merger with AstraZeneca is expected to close in the third quarter.
Vertex (VRTX) Q1 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Vertex (VRTX) beats both earnings and sales estimates in Q1 and keeps product sales outlook for 2021.